News zum Sektor Gesundheit aus Norwegen

 

Tromsø, Norway, November 28th, 2025 - Reference is made to the stock exchange announcement published by ArcticZymes Technologies ASA (the "Company", OSE: AZT) on 25 November 2025 announcing the initiation of a share buyback program pursuant to the authorization granted by the Annual General Meeting held on 27 May 2025. The share buyback program has now been completed. From and including 25 November 2025 to and including 28 November 2025, the Company has purchased a total of 31,365 own shares at an average price of NOK 22.5037 per share. Please see the attached table for further details....

Oslo, Norway, 28 November 2025 – Zelluna (OSE: ZLNA), a company pioneering allogeneic “off-the-shelf” T Cell Receptor-based Natural Killer (TCR-NK) cell therapies for the treatment of cancer, today announced the appointment of Geir Christian Melen as new Chief Financial Officer, effective 01 January 2026. Hans Vassgård Eid will be stepping down as CFO of Zelluna ASA from the end of December 2025 and supporting the transition thereafter....

27 November 2025: Reference is made to the stock exchange announcements published by Oncoinvent ASA (the "Company") on 14 November 2025 and on 17 November 2025, regarding the commencement of the subscription period in the fully underwritten rights issue of 260,000,000 new shares in the Company (the "Rights Issue") and the receipt of subscription rights in the Rights Issue by certain primary insiders and certain close associates of primary insiders of the Company. As of this date, 27 November 2025, the Company has been informed that certain primary insiders and/or close associates of primary...

Reference is made to the stock exchange announcement made by Zelluna ASA (the "Company") on 3 November 2025 regarding the allocation of 5,500,000 new shares in the Company in a private placement (the "Private Placement"), divided on a first tranche of 3,729,774 new shares and a second tranche of 1,770,226 new shares ("Tranche 2"), and the allocation of 315,639 new shares in a retail offering via the PrimaryBid Platform. ...

OSLO, NORWAY – November 27, 2025: Genetic Analysis AS ("GA" or the "Company") hereby publishes the interim report for Q3, and the first nine months of 2025. The report is available as an attached file to this release and on the Company's website. Below is a summary of the report. Ronny Hermansen, CEO of Genetic Analysis, comments: “The third quarter was marked by consistent progress across Genetic Analysis' commercial and development activities, underscoring continued execution on our long-term growth strategy. The third quarter was influenced by the slower summer holiday period, but sales...

Oslo, November 25, 2025: Zelluna ASA held its extraordinary general meeting today November 25, 2025. All the matters on the agenda were approved. ...

(Tromsø/Oslo, 25 November 2025) ArcticZymes Technologies ASA (OSE:AZT) will today present at DNB Carnegie's Nordic Healthcare Conference 2025 in Oslo. Estimated start of the presentation will be at 09.25 CET Speaker will be CEO, Michael Akoh Please find the presentation enclosed For further information: Børge Sørvoll CFO +47 950 90 187 ir@arcticzymes.com...

Um den gesamten Artikel unter de.investing.com zu lesen, klicken Sie bitte auf die Überschrift...

Christoph Baldegger, primary insider and member of the Board of Directors in Hofseth BioCare ASA ("HBC"), has subscribed for 368,320 Offer shares in the Subsequent Offering and Mr. Baldegger will hold 3,616,296 shares in HBC after the share capital is registered, equal to approximately 0.92 % of the total outstanding A-shares with voting rights. ...

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART DIRECTLY OR INDIRECTLY, IN AUSTRALIA, CANADA, JAPAN OR THE UNITED STATES OR ANOTHER JURISDICTION IN WHICH THE RELEASE, PUBLICATION OR DISTRIBUTION WOULD BE UNLAWFUL. THIS ANNOUNCEMENT DOES NOT CONSTITUTE AN OFFER OF ANY OF THE SECURITIES DESCRIBED HEREIN....

SAN FRANCISCO, Nov. 20, 2025 (GLOBE NEWSWIRE) -- Omada Health (Nasdaq: OMDA), the virtual between-visit healthcare provider, today announced that members of senior management will participate in the 8th Annual Evercore Healthcare Conference, taking place in Miami, including a fireside chat on Wednesday, December 3, 2025, at 1:20 pm ET. The webcast will be available online at https://investors.omadahealth.com/news-events/events. A replay will also be available at the same link following the event....

Hofseth BioCare ASA held an Extraordinary General Meeting on 20 November 2025. All proposals were resolved as presented in the notice issued on 30 October 2025....

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART DIRECTLY OR INDIRECTLY, IN AUSTRALIA, CANADA, JAPAN OR THE UNITED STATES OR ANOTHER JURISDICTION IN WHICH THE RELEASE, PUBLICATION OR DISTRIBUTION WOULD BE UNLAWFUL. THIS ANNOUNCEMENT DOES NOT CONSTITUTE AN OFFER OF ANY OF THE SECURITIES DESCRIBED HEREIN....

Hofseth BioCare (HBC), a global leader in sustainable marine-based nutrition, today announced a strategic product partnership with Metabolic Elite, with formulations being guided by key opinion leader and nutrition expert Jim LaValle. The collaboration unites HBC's rigorously tested nutritional ingredients, including award-winning ProGo® bioactive peptides, with Metabolic Elite's advanced performance formulations and LaValle's expertise in precision health....

OSLO, Norway , Nov. 19, 2025 /PRNewswire/ -- Photocure ASA (OSE: PHO), the Bladder Cancer Company, announces the publication of the study "Hexaminolevulinate-enhanced photodynamic diagnosis in the management of non-muscle-invasive bladder cancer (NMIBC): The influence of differing......

Um den gesamten Artikel unter de.investing.com zu lesen, klicken Sie bitte auf die Überschrift...

Oslo, Norway, November 18, 2025 – Lytix Biopharma AS (“Lytix” or the “Company”) today releases its results for the third quarter of 2025. Post-quarter-end brought a surge of positive news for Lytix's first asset, ruxotemitide (formerly LTX-315), with two key clinical results in both neoadjuvant melanoma and basal cell carcinoma (BCC). These findings, outlined below, have prompted the company to accelerate its development plan, focusing on the fastest route to bring the groundbreaking drug to patients. Q3 2025 highlights and developments · Licensing partner Verrica Pharmaceuticals...

Oslo, Norway, 17 November, 2025: Reference is made to the stock exchange announcement made by Zelluna ASA (the "Company") on 3 November 2025 regarding the successful private placement of 5,500,000 new shares (the "Private Placement"), divided on a first tranche of 3,729,774 new shares ("Tranche 1") and a second tranche of 1,770,226 new shares, and the allocation of 315,639 new shares in the retail offering carried out via the PrimaryBid platform (the "Retail Offering")....

OSLO, NORWAY – 17 November 2025: Microbiome DX company Genetic Analysis AS (“GA”) is pleased to announce the completion of the biomarker panel development in its ongoing IBD Precision Dx project. This marks a major milestone in the project, with GA now progressing to the final validation phase and completion of the software development. The goal of the IBD Precision Dx project is to develop a microbiome-based diagnostic test capable of predicting disease course in Ulcerative Colitis (UC) patients, thereby supporting earlier and more targeted treatment decisions. The project is conducted in...

NOT FOR DISTRIBUTION OR RELEASE, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, CANADA, AUSTRALIA, THE HONG KONG SPECIAL ADMINISTRATIVE REGION OF THE PEOPLE'S REPUBLIC OF CHINA OR JAPAN OR ANY OTHER JURISDICTION IN WHICH THE DISTRIBUTION OR RELEASE WOULD BE UNLAWFUL. OTHER RESTRICTIONS ARE APPLICABLE. PLEASE SEE THE IMPORTANT NOTICE AT THE END OF THIS ANNOUNCEMENT 17 November 2025: Reference is made to the stock exchange announcements published by Oncoinvent ASA (the "Company") on 30 June 2025 and 4 August 2025, and subsequent announcements, regarding the contemplated fully...